WWE SmackDown results, review, grades for Oct. 16: Cody Rhodes punts Baron Corbin as Randy Orton watches - CBS Sports

Tonight’s rivalry-fueled WWE SmackDown will feature a face-to-face confrontation between Cody Rhodes and Randy Orton as demanded by Rhodes. The grudge continues between Paige and Nikki Bella as they go one-on-one in a rematch from their September 11 bout that Bella won. Former friends and former WWE Tag Team Champions Damian Priest and R-Truth will […]

Alright everyone, it’s time for WWE Smackdown. We’re on the heels of Money in the Bank which was kind of a giant nothing burger, doubly so on the Smackdown side of things as there wasn’t a Smackdown match on the event. But Tiffany Stratton and Penta won the briefcases, so now we’re doing another friend turning slow burn on the women’s side of things. On RAW that’s what Liv Morgan and Roxanne Perez are doing, and have been doing for ages now, while on Smackdown now we get to look forward to Tiffany turning on WWE women’s champion Chelsea Green. Penta was a good choice for the men’s briefcase, though the Smackdown main event scene is packed right now and moving him over might be a logistical error if he does cash in on Sami Zayn. We’ve got to build to Crown Jewel quickly, and hope the Riyadh airport doesn’t get bombed again, so expect some more champion vs. champion stuff. Though Liv vs. Green and Roman Reigns vs. Sami don’t feel like super important matches, but maybe that’s just me being incredibly jaded. Tonight Nikki Bella gets to rematch Paige and Nikki trying for a title run in 2026 is just divine punishment aimed at wrestling.

We're still dealing with the fallout from the Money in the Bank PLE, but as of now, WWE is still preparing for Crown Jewel on November 7.

Fibrosis, the dense scar tissue that can entangle peritoneal tumors and the healthy organs around them, is one reason cytoreduction surgery is denied to a portion of patients with appendiceal and other abdominal cancers. Allegheny Health Network Cancer Center’s newly launched RANDY’S Trial is built on a direct answer to that problem: test whether FDA-approved drugs already on the market can remodel that scar tissue and bring more patients into surgical eligibility. The trial did not emerge from a pharma pipeline or an NIH grant. A single community gala, the La Sera d’Oro event, raised $44,000 in 2025 to fund it. The acronym stands for Repurposed And Naturally-Derived Drugs for the Treatment of Fibrosis in Peritoneal Carcinomatosis. Principal investigator Patrick Wagner, a surgical oncologist at AHN, is leading a multidisciplinary team that will evaluate existing medications for their ability to break down or remodel abdominal scar tissue. The mechanism matters because fibrosis does two things that complicate surgery: it obscures the boundary between healthy and diseased tissue, and it can trap cancer cells that are then left behind when a surgeon separates planes.